SCHEMBL3010815

SCHEMBL3010815

Cc1cccc(Cc2csc(N3CCC(S(=O)(=O)c4ccc([N+](=O)[O-])cc4)CC3)n2)c1C

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
RAB9A P51151 3/20 0.40
NPC1 O15118 2/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 4/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
GBA1 P04062 1/20 0.35
DNM1L O00429 1/20 0.34
EGFR P00533 2/20 0.33
NPBWR1 P48145 1/20 0.33
MCHR1 Q99705 1/20 0.33
MAPK1 P28482 2/20 0.32
LMNA P02545 1/20 0.32
PRKCQ Q04759 1/20 0.32
MITF O75030 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008969 0.93 MEN1 (0.39) KMT2AMEN1RAB9ANPC1POLB
SCHEMBL3007070 0.92 MEN1 (0.38) KMT2AMEN1RAB9ANPC1POLB
SCHEMBL3012757 0.90 MEN1 (0.40) KMT2AMEN1RAB9ANPC1POLB
SCHEMBL3021393 0.90 GBA1 (0.42) KMT2AMEN1RAB9ANPC1POLB
SCHEMBL3013182 0.89 LMNA (0.37) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL3001734 0.88 SMN1; SMN2 (0.40) KMT2AMEN1RAB9ANPC1MAPT
SCHEMBL3015608 0.88 SMN1; SMN2 (0.38) KMT2AMEN1RAB9ANPC1POLB
SCHEMBL3011182 0.87 VCAM1 (0.38) MAPTSMN1; SMN2NPBWR1MCHR1MAPK1
SCHEMBL3013464 0.87 GBA1 (0.35) KMT2AMEN1RAB9ANPC1POLB
SCHEMBL3020316 0.87 GBA1 (0.35) KMT2AMEN1RAB9ANPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KMT2A 2680/4885MEN1 454/4885RAB9A 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.